Company profile
PROCEPT BioRobotics
PROCEPT BioRobotics develops surgical robotic systems for urology. Its AquaBeam platform delivers Aquablation therapy, an image-guided, robotic-assisted wa...
Facts
- Segment
- SURGICAL
- Country
- United States
- Headquarters
- San Jose, CA
- Ticker
- PRCT
- Website
- https://www.procept-biorobotics.com/
About PROCEPT BioRobotics
PROCEPT BioRobotics manufactures the AquaBeam and HYDROS surgical robotic systems for Aquablation treatment of benign prostatic hyperplasia. The procedure combines real-time ultrasound and cystoscopy with surgeon-defined treatment planning, then uses a robotically controlled, heat-free waterjet to remove targeted prostate tissue.
HYDROS adds FirstAssist AI image recognition to identify anatomy and suggest a personalised plan, alongside integrated digital imaging and guided operating-room workflow. The system is FDA-cleared and CE-marked, entered international commercial rollout in 2026 and uses a single-use handpiece for each procedure. PROCEPT reported approximately 12,200 US Aquablation procedures during the first quarter of 2026 while continuing clinical research in BPH and investigational prostate-cancer applications.
Market context
DEPLOYMENT
Summary
Type: Surgical robotics
Core: AquaBeam
Function: Surgery
Audience: Healthcare providers
Products
- AquaBeam Robotic System — surgical_robot